 Ataxia Telangiectasia Mutated Proteins
"Ataxia Telangiectasia Mutated Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of PROTEIN-SERINE-THREONINE KINASES which activate critical signaling cascades in double strand breaks, APOPTOSIS, and GENOTOXIC STRESS such as ionizing ultraviolet A light, thereby acting as a DNA damage sensor. These proteins play a role in a wide range of signaling mechanisms in cell cycle control.
| Descriptor ID |
D064007
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.097 D12.776.157.687.125 D12.776.660.720.125
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ataxia Telangiectasia Mutated Proteins".
Below are MeSH descriptors whose meaning is more specific than "Ataxia Telangiectasia Mutated Proteins".
This graph shows the total number of publications written about "Ataxia Telangiectasia Mutated Proteins" by people in this website by year, and whether "Ataxia Telangiectasia Mutated Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 3 | 3 | | 2006 | 0 | 2 | 2 | | 2007 | 0 | 1 | 1 | | 2009 | 0 | 3 | 3 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 2 | 2 | | 2014 | 1 | 2 | 3 | | 2015 | 1 | 1 | 2 | | 2016 | 2 | 2 | 4 | | 2017 | 2 | 2 | 4 | | 2018 | 1 | 0 | 1 | | 2019 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 | | 2022 | 0 | 2 | 2 | | 2024 | 1 | 1 | 2 | | 2025 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Ataxia Telangiectasia Mutated Proteins" by people in Profiles.
-
Sharma S, Ali R, Bouska A, Jochum D, Kesireddy M, Mahov S, Lownik J, Zhang W, Lone W, Soma MA, Gamboa A, Devarakonda V, El-Gamal D, Fariha A, Mansoor A, Stewart D, Martin P, Link BK, Advani RH, Barr PM, Goy AH, Mehta A, Kamdar M, Stephens DM, Bachanova V, Smith L, Morin R, Pararajalingam P, Lunning MA, Fu K, Weisenburger D, Chan WC, Khoury J, Greiner TC, Vose JM, Merchant A, Bi C, Iqbal J. Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma. Nat Commun. 2025 Nov 05; 16(1):9762.
-
Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross EA, Grundy E, Choi W, Dinney CPN, Lee IC, Fong M, Scott Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner SP, Flaig TW, McConkey DJ. Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. Eur Urol. 2024 Oct; 86(4):297-300.
-
Chen J, Laverty DJ, Talele S, Bale A, Carlson BL, Porath KA, Bakken KK, Burgenske DM, Decker PA, Vaubel RA, Eckel-Passow JE, Bhargava R, Lou Z, Hamerlik P, Harley B, Elmquist WF, Nagel ZD, Gupta SK, Sarkaria JN. Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Sci Transl Med. 2024 02 14; 16(734):eadj5962.
-
Davis SL, Hartman SJ, Bagby SM, Schlaepfer M, Yacob BW, Tse T, Simmons DM, Diamond JR, Lieu CH, Leal AD, Cadogan EB, Hughes GD, Durant ST, Messersmith WA, Pitts TM. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. BMC Cancer. 2022 Oct 29; 22(1):1107.
-
Park HJ, Gregory MA, Zaberezhnyy V, Goodspeed A, Jordan CT, Kieft JS, DeGregori J. Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation. Elife. 2022 10 19; 11.
-
Li Z, Wang-Heaton H, Cartwright BM, Makinwa Y, Hilton BA, Musich PR, Shkriabai N, Kvaratskhelia M, Guan S, Chen Q, Yu X, Zou Y. ATR prevents Ca2+ overload-induced necrotic cell death through phosphorylation-mediated inactivation of PARP1 without DNA damage signaling. FASEB J. 2021 05; 35(5):e21373.
-
Mensah KA, Chen JW, Schickel JN, Isnardi I, Yamakawa N, Vega-Loza A, Anolik JH, Gatti RA, Gelfand EW, Montgomery RR, Horowitz MC, Craft JE, Meffre E. Impaired ATM activation in B cells is associated with bone resorption in rheumatoid arthritis. Sci Transl Med. 2019 11 20; 11(519).
-
Molitoris BA. DNA damage response protects against progressive kidney disease. J Clin Invest. 2019 11 01; 129(11):4574-4575.
-
Minto H, Mensah KA, Reynolds PR, Meffre E, Rubtsova K, Gelfand EW. A novel ATM mutation associated with elevated atypical lymphocyte populations, hyper-IgM, and cutaneous granulomas. Clin Immunol. 2019 03; 200:55-63.
-
Zhang Y, Lee JH, Paull TT, Gehrke S, D'Alessandro A, Dou Q, Gladyshev VN, Schroeder EA, Steyl SK, Christian BE, Shadel GS. Mitochondrial redox sensing by the kinase ATM maintains cellular antioxidant capacity. Sci Signal. 2018 07 10; 11(538).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|